Developing new antimicrobial therapies to treat resistant Gram-negative infections

Deprioritized
Strategic Focus

 

cUTI: complicated Urinary Tract Infection; MDR: multi-drug resistant; ESBL: extended spectrum beta-lactamases.

Only ZEMDRI has been approved for commercial use. See full Prescribing Information. All other product candidates are investigational only, potential treatments, and have not been approved for commercial use.